Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER3 | P43115 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TYMS | P04818 | 2/20 | 0.39 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.39 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.39 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.38 |
| ▸ | G6PD | P11413 | 1/20 | 0.38 |
| ▸ | CCR6 | P51684 | 1/20 | 0.38 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31241186 | 1.00 | PTGER3 (0.45) | PTGER3LMNAMEN1KMT2ATHRB | |
| SCHEMBL3684095 | 0.82 | PTGER3 (0.43) | PTGER3LMNAMEN1KMT2ATDP1 | |
| SCHEMBL30548745 | 0.80 | MAP2K2 (0.48) | LMNATDP1TYMSHAO1MAP2K2 | |
| SCHEMBL193869 | 0.79 | KMT2A (0.50) | LMNAMEN1KMT2ATHRBBLM | |
| SCHEMBL7188592 | 0.78 | ALDH1A1 (0.45) | LMNAMEN1KMT2ATHRBBLM | |
| SCHEMBL7931764 | 0.78 | PTGER3 (0.57) | PTGER3LMNASMN1; SMN2HDAC1HDAC8 | |
| SCHEMBL7822972 | 0.78 | PTGER3 (0.57) | PTGER3LMNASMN1; SMN2HDAC1HDAC8 | |
| SCHEMBL6926885 | 0.78 | PDE7A (0.48) | LMNAMEN1KMT2ATDP1SMN1; SMN2 | |
| SCHEMBL2271692 | 0.76 | HDAC1 (0.57) | LMNAMEN1KMT2ATHRBBLM | |
| SCHEMBL1466237 | 0.76 | MEN1 (0.43) | LMNAMEN1KMT2ATHRBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718849-B2 | Sulfur chelated ruthenium compounds useful as olefin metathesis catalysts | BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY (IL) | 2017-08-01 | — | — | US | disclosed |
| US-20140155511-A1 | SULFUR CHELATED RUTHENIUM COMPOUNDS USEFUL AS OLEFIN METATHESIS CATALYSTS | BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY (IL) | 2014-06-05 | — | — | US | disclosed |
| US-8513151-B2 | Sulfur chelated ruthenium compounds useful as olefin metathesis catalysts | BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY (IS) | 2013-08-20 | — | — | US | disclosed |
| US-20100113722-A1 | SULFUR CHELATED RUTHENIUM COMPOUNDS USEFUL AS OLEFIN METATHESIS CATALYSTS | BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY (IL) | 2010-05-06 | — | — | US | disclosed |
| US-6242493-B1 | PROSTAGLANDIN INHIBITORS; ANALGESICS, ANTIPYRETICS, ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA & CO. (CA) | 2001-06-05 | — | — | US | disclosed |
| EP-1071648-A2 | CARBOXYLIC ACIDS AND ACYLSULFONAMIDES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Merck Frosst Canada & Co. (CA) | 2001-01-31 | — | — | EP | disclosed |
| WO-1999047497-A2 | CARBOXYLIC ACIDS AND ACYLSULFONAMIDES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK FROSST CANADA & CO. (CA) | 1999-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155511-A1 | SULFUR CHELATED RUTHENIUM COMPOUNDS USEFUL AS OLEFIN METATHESIS CATALYSTS | C1S, SCO2, AP1S1 | PTGER3 3717/4885LMNA 4771/4885MEN1 1010/4885 |
| US-20100113722-A1 | SULFUR CHELATED RUTHENIUM COMPOUNDS USEFUL AS OLEFIN METATHESIS CATALYSTS | C1S, SCO2, AP1S1 | PTGER3 3717/4885LMNA 4771/4885MEN1 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.